Strs Ohio acquired a new stake in Chimerix, Inc. (NASDAQ:CMRX – Get Rating) during the third quarter, Holdings Channel reports. The fund acquired 45,400 shares of the biopharmaceutical company’s stock, valued at approximately $87,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Chimerix by 14.2% in the 1st quarter. State Street Corp now owns 4,561,868 shares of the biopharmaceutical company’s stock valued at $20,893,000 after purchasing an additional 568,498 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Chimerix by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 3,832,252 shares of the biopharmaceutical company’s stock worth $17,552,000 after acquiring an additional 105,441 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Chimerix by 11.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,951,521 shares of the biopharmaceutical company’s stock worth $8,938,000 after acquiring an additional 206,990 shares during the period. Monaco Asset Management SAM purchased a new position in shares of Chimerix during the 2nd quarter worth $3,077,000. Finally, Penn Capital Management Company LLC purchased a new position in shares of Chimerix during the 2nd quarter worth $1,764,000. Hedge funds and other institutional investors own 58.03% of the company’s stock.
Analyst Ratings Changes
Separately, StockNews.com upgraded Chimerix from a “hold” rating to a “buy” rating in a report on Friday, November 4th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Chimerix has a consensus rating of “Buy” and an average price target of $8.50.
Chimerix Trading Up 0.5 %
Chimerix (NASDAQ:CMRX – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.10 by $0.65. The firm had revenue of $32.56 million for the quarter, compared to analyst estimates of $205.30 million. Chimerix had a net margin of 464.75% and a return on equity of 147.04%. Equities research analysts forecast that Chimerix, Inc. will post 1.97 earnings per share for the current year.
Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
- Get a free copy of the StockNews.com research report on Chimerix (CMRX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.